期刊文献+
共找到806篇文章
< 1 2 41 >
每页显示 20 50 100
To Explore the Causal Link between Genetic Predisposition to Alcohol Consumption and Type 2 Diabetes Mellitus
1
作者 Qingxiang Zeng Minghua Dong 《Journal of Biosciences and Medicines》 2024年第12期538-549,共12页
Type 2 diabetes is a chronic metabolic disorder, and the behavior and quantity of alcohol consumption may be influenced by genetic factors. Moderate alcohol consumption has been associated with a reduced risk of type ... Type 2 diabetes is a chronic metabolic disorder, and the behavior and quantity of alcohol consumption may be influenced by genetic factors. Moderate alcohol consumption has been associated with a reduced risk of type 2 diabetes, whereas excessive drinking may increase the risk. Alcohol consumption might indirectly contribute to the development of type 2 diabetes through factors such as body mass index (BMI). This paper explores the complex relationship between alcohol consumption and type 2 diabetes, investigating the causal association using Mendelian randomization (MR) methodology. Individual genetic background significantly impacts drinking habits, with certain genetic variants being linked to higher alcohol consumption tendencies, which also influence the risk of type 2 diabetes. The study employed MR methods, utilizing genetic variants as instrumental variables to assess the causal relationship between alcohol consumption and type 2 diabetes. Data from the European population samples obtained from the IEU Open GWAS Project database were used, including summary data from genome-wide association studies (GWAS) related to alcohol consumption and type 2 diabetes. The inverse variance weighted (IVW) method was applied to estimate the causal effect. The IVW results indicated no statistically significant association between alcohol consumption and increased risk of type 2 diabetes (OR = 1.0046, 95% CI: [0.8722, 1.1571], P = 0.9495), suggesting no significant causal relationship between genetically predicted alcohol consumption and type 2 diabetes risk. These findings contribute to future research and development in the prevention and management of type 2 diabetes. 展开更多
关键词 type 2 Diabetes Capacity for alcohol Mendelian Randomization
暂未订购
Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus 被引量:8
2
作者 Wei-Dong Li Kun-Fa Fu +4 位作者 Gui-Mei Li Yan-Shu Lian Ai-Min Ren Yun-Jue Chen Jin-Rong Xia 《World Journal of Gastroenterology》 SCIE CAS 2015年第32期9607-9613,共7页
AIM: To compare and analyze the effects of obesity and non-alcoholic fatty liver disease(NAFLD) on the incidence of type 2 diabetes mellitus(T2DM) in Chinese subjects.METHODS: In 2008, a population of 4847 subjects wa... AIM: To compare and analyze the effects of obesity and non-alcoholic fatty liver disease(NAFLD) on the incidence of type 2 diabetes mellitus(T2DM) in Chinese subjects.METHODS: In 2008, a population of 4847 subjects was randomly sampled from 17 medical units for enrollment in this cohort study. Baseline information was obtained via a questionnaire on general information, physical examination(height, weight, and blood pressure), laboratory tests(triglycerides, total cholesterol, fasting blood glucose, alanine aminotransferase(ALT), uric acid, and creatinine), B-mode ultrasound, and ECG screening. The incidence of T2 DM after four years of follow-up was calculated. Numeric variable data was tested for normality, with the data expressed as mean ± SD. Kaplan-Meier analysis was performed to calculate the cumulative incidence. The Cox proportional hazards model was used to analyze the relative risk(RR) of different body mass index(BMI) levels and NAFLD on T2 DM, as well as analyzingthe RR adjusted for age, sex, blood pressure, lipids, transaminases, uric acid, and creatinine.RESULTS: A total of 4736(97.71%) subjects completed 4-year follow-up, with a median follow-up time of 3.85 years, totaling 17223 person-years. 380 subjects were diagnosed with T2 DM, with a cumulative incidence of 8.0%. The cumulative incidence of T2 DM in the NAFLD and control groups was 17.4% vs 4.1%(P < 0.001), respectively, while the incidence in overweight and obese subjects was 11.0% vs 15.8%(P < 0.001), respectively. The incidence of T2 DM increased with an increase in baseline BMI. Cox regression analysis showed that the risk of T2 DM in the NAFLD group(RR = 4.492, 95%CI: 3.640-5.542) after adjustment for age, sex, blood pressure, lipids, ALT, uric acid, and creatinine was 3.367(2.367-4.266), whi le t he value(RR, 95%CI) in overweight and obese subjects after adjustment for age, sex, BMI, blood pressure, lipids and other factors was 1.274(0.997-1.629) and 1.554(1.140-2.091), respectively. Stratification of three BMI levels(BMI < 24 kg/m2, 2 4 k g / m2 ≤ B M I < 2 8 k g / m2, B M I ≥ 2 8 k g / m2) showed that the risk of T2 DM in the NAFLD group was significantly higher than that in the control group(RR = 3.860, 4.049 and 3.823, respectively).CONCLUSION: Compared with BMI, NAFLD could be better at forecasting the risk of T2 DM in Chinese subjects, and may be a high risk factor for T2 DM, independent of overweight/obesity. 展开更多
关键词 Non-alcoholic FATTY LIVER disease type 2 DIABETES
暂未订购
Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats 被引量:26
3
作者 Qin He Jin-Ke Li +5 位作者 Fang Li Ru-Gui Li Guo-Qing Zhan Gang Li Wei-Xing Du Hua-Bing Tan 《World Journal of Gastroenterology》 SCIE CAS 2015年第7期2058-2066,共9页
AIM:To explore the mechanism of action of gypenosides(GPs)on type 2 diabetes mellitus and non-alcoholic fatty liver disease(T2DM-NAFLD)in rats.METHODS:Sixty rats were randomly divided into a healthy group,an untreated... AIM:To explore the mechanism of action of gypenosides(GPs)on type 2 diabetes mellitus and non-alcoholic fatty liver disease(T2DM-NAFLD)in rats.METHODS:Sixty rats were randomly divided into a healthy group,an untreated disease model group andGP-treatment groups.The study involved the evaluation of biochemical parameters,including serum aspartate transaminase(AST),alanine transferase(ALT),blood glucose(BG),triglycerides(TG)and total cholesterol(TC).Additionally,the protective effect of the treatments were confirmed histopathologically and the expression of TNF-αand NF-κB in the rat liver was analyzed using immunohistochemistry.The expression of proliferatoractivated receptor gamma(PPARγ)and cytochrome P450(CYP450)1A1 m RNA was determined by quantitative RTPCR.RESULTS:GP treatments at oral doses of 200,400,and800 mg/kg per day significantly decreased the levels of serum AST and ALT(P<0.05,P<0.01),especially at the dose of 800 mg/kg per day.To a similar extent,GP at800 mg/kg per day reduced the levels of BG(4.19±0.47,P<0.01),TG(80.08±10.05,P<0.01),TC(134.38±16.39,P<0.01)and serum insulin(42.01±5.04,P<0.01).The expression of TNF-αand NF-κB measured by immunohistochemistry was significantly reduced by GPs in a dose-dependent manner,and the expression of PPARγand CYP4501A1 m RNA,as measured using quantitative real-time PCR,were significantly down-regulated by GPs.Moreover,GPs decreased the infiltration of liver fats and reversed the histopathological changes in a dosedependent manner.CONCLUSION:This study suggests that GPs have a protective effect against T2DM-NAFLD by down-regulating the expression of TNF-αand NF-κB proteins,and PPARγand CYP4501A1 m RNAs. 展开更多
关键词 GYPENOSIDES type 2 DIABETES MELLITUS Non-alcoholic
暂未订购
Mori Cortex extract ameliorates nonalcoholic fatty liver disease( NAFLD) and insulin resistance in high-fat-diet/streptozotocininduced type 2 diabetes in rats 被引量:10
4
作者 MA Li-Li YUAN Yan-Yan +5 位作者 ZHAO Ming ZHOU Xin-Rong Tashina Jehangir WANG Fu-Yan XI Yang BU Shi-Zhong 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2018年第6期411-417,共7页
Nonalcoholic fatty liver disease(NAFLD) and type 2 Diabetes Mellitus(T2 DM) are highly prevalent diseases and are closely associated, with NAFLD being present in the majority of T2 DM patients. In Asian traditional me... Nonalcoholic fatty liver disease(NAFLD) and type 2 Diabetes Mellitus(T2 DM) are highly prevalent diseases and are closely associated, with NAFLD being present in the majority of T2 DM patients. In Asian traditional medicine, Mori Cortex is widely used for the treatment of diabetes and hyperlipidemia. However, whether it has a therapeutic effect on T2 DM associated with NAFLD is still unknown. The present study showed that the oral treatment with Mori Cortex extract(MCE; 10 g·kg-1·d-1) lowered the blood lipid levels and reversed insulin resistance(IR) in high fat-diet/streptozotocin-induced type 2 diabetes in rats. The expression levels of sterol receptor element-binding protein-1 c(SREBP-1 c) and carbohydrate-responsive element binding protein(Ch REBP), which are involved in steatosis in NAFLD rats, were measured in the liver samples. MCE decreased the protein and m RNA expression levels of SREBP-1 c and Ch REBP. In conclusion, down-regulation of SREBP-1 c and Ch REBP might contribute to the protective effect of MCE on hepatic injury and IR in the rats with T2 DM associated with NAFLD. 展开更多
关键词 Mori CORTEX EXTRACT type 2 diabetes Non-alcoholic fatty liver STEROL receptor element-binding protein-It Carbohy-drate-responsive ELEMENT binding protein
原文传递
Napelline-type C_(20)-diterpenoid alkaloid iminiums from an aqueous extract of ‘‘fu zi'': Solvent-/base-/acid-dependent transformation and equilibration between alcohol iminium and aza acetal forms 被引量:12
5
作者 Xian-Hua Meng Zhi-Bo Jiang +3 位作者 Cheng-Gen Zhu Qing-Lan Guo Cheng-Bo Xu Jian-Gong Shi 《Chinese Chemical Letters》 SCIE CAS CSCD 2016年第7期993-1003,共11页
Three new napelline-type C20-diterpenoid alkaloids,named aconicarmichinium A and B trifluoroacetates(1 and 2) and aconicarmichinium C chloride(3),were isolated from an aqueous extract of "fu zi",the lateral root... Three new napelline-type C20-diterpenoid alkaloids,named aconicarmichinium A and B trifluoroacetates(1 and 2) and aconicarmichinium C chloride(3),were isolated from an aqueous extract of "fu zi",the lateral roots of Aconitum carmichaelii.Their structures were elucidated by extensive spectroscopic data analysis.Compounds 1-3 represent the first examples of napelline-type C20 diterpenoid alkaloid alcohol iminiums,of which the structures were fully characterized.In addition,transformation and equilibration between the alcohol iminiums(1-3) and the aza acetals la-3a were investigated by measurements of the NMR spectra in protic and aprotic deuterium solvents including alkali pyridine-d5,along with evaporation under reduced pressure and gradual additions of TFA,AcOH,and HC1.The results demonstrated that the transformation and equilibration were solvent-,base-,and acid-dependent.Especially,in aqueous biological fluid,these C20-diterpenoid alkaloids would more likely exist as the alcohol iminiums accompanied by anion counterparts in biosystems to increase their solubility, bioavailability, transportations, and functions.The absolute configurations of 1-3 were confirmed by X-ray crystallographic analysis of 2a. 展开更多
关键词 Aconitum carmichaelii Ranunculaceae Napelline-type C20-diterpenoid alkaloid Aconicarmichiniums A–C alcohol iminium and aza acetal forms of the diterpenoid alkaloid Transformation and equilibration
原文传递
Effect of nuclear factor-κB and angiotensin Ⅱ receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease 被引量:4
6
作者 Dao-Yu Tan Hai-Yan Shi +2 位作者 Chang-Ping Li Xiao-Ling Zhong Ming Kang 《World Journal of Gastroenterology》 SCIE CAS 2015年第19期5877-5883,共7页
AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats... AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats were randomly divided into three groups:the control group(normal diet), the model group,and the intervention group(10 wk of a high-fat diet feeding, followed by an intraperitoneal injection of PDTC); 6 rats in each group were sacrificed at 6, 10,and 14 wk. After sacrifice, liver tissue was taken,paraffin sections of liver tissue specimens were prepared, hematoxylin and eosin(HE) staining was performed, and pathological changes in liver tissue(i.e., liver fibrosis) were observed by light microscopy.NF-κB expression in liver tissue was detected by immunohistochemistry, and the expression of AT1 R in the liver tissue was detected by reverse transcriptionpolymerase chain reaction(RT-PCR). The data are expressed as mean ± SD. A two-sample t test was used to compare the control group and the model group at different time points, paired t tests were used to compare the differences between the intervention group and the model group, and analysis of variance was used to compare the model group with the control group. Homogeneity of variance was analyzed with single factor analysis of variance. H variance analysis was used to compare the variance. P < 0.05 wasconsidered statistically significant.RESULTS: The NAFLD model was successful after 6wk and 10 wk. Liver fibrosis was found in four rats in the model group, but in only one rat in the intervention group at 14 wk. Liver steatosis, inflammation, and fibrosis were gradually increased throughout the model. In the intervention group, the body mass,rat liver index, serum lipid, and transaminase levels were not increased compared to the model group.In the model group, the degree of liver steatosis was increased at 6, 10, and 14 wk, and was significantly higher than in the control group(P < 0.01). In the model group, different degrees of liver cell necrosis were visible and small leaves, punctated inflammation,focal necrosis, and obvious ballooning degeneration were observed. Partial necrosis and confluent necrosis were observed. In the model group, liver inflammatory activity scores at 6, 10, and 14 wk were higher than in the control group(P < 0.01). Active inflammation in liver tissue in the intervention group was lower than in the model group(P < 0.05). HE staining showed liver fibrosis only at 14 wk in 4/6 rats in the model group and in 1/6 rats in the intervention group. NF-κB positive cells were stained yellow or ensemble yellow,and NF-κB was localized in the cytoplasm and/or nucleus. The model group showed NF-κB activation at6, 10, and 14 wk in liver cells; at the same time points,there were statistically significant differences in the control group(P < 0.01). Over time, NF-κB expression increased; this was statistically lower(P < 0.05) at14 weeks in the intervention group compared to the model group, but significantly increased(P < 0.05)compared with the control group; RT-PCR showed that AT1 R mRNA expression increased gradually in the model group; at 14 wk, the expression was significantly different compared with expression at 10 weeks as well as at 6 weeks(P < 0.05). In the model group, AT1 R mRNA expression was significantly higher than at the same time point in the control group(P <0.01).CONCLUSION: With increasing severity of NAFLD,NF-κB activity is enhanced, and the inhibition of NF-κB activity may reduce AT1 R mRNA expression in NAFLD. 展开更多
关键词 Non-alcoholic FATTY liver disease Nuclearfactor-κB ANGIOTENSIN RECEPTOR type 1 Rats Liverfibrosis
暂未订购
微RNA-128-3p、沉默信息调节因子1(SIRT1)和AMP活化蛋白激酶(AMPK)对2型糖尿病合并非酒精性脂肪性肝病的诊断价值 被引量:2
7
作者 李居一 倪英群 +1 位作者 张媛媛 刘怀珍 《临床肝胆病杂志》 北大核心 2025年第3期453-460,共8页
目的分析2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者外周血中微RNA(miRNA)-128-3p、沉默信息调节因子1(SIRT1)和AMP活化蛋白激酶(AMPK)的表达情况,探讨mi RNA-128-3p对T2DM患者发生NAFLD的预测作用。方法选取2022年9月—2023年... 目的分析2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者外周血中微RNA(miRNA)-128-3p、沉默信息调节因子1(SIRT1)和AMP活化蛋白激酶(AMPK)的表达情况,探讨mi RNA-128-3p对T2DM患者发生NAFLD的预测作用。方法选取2022年9月—2023年8月在安徽中医药大学第一附属医院住院的80例T2DM患者,分为T2DM组(40例)和合并NAFLD组(40例),并依据肝纤维化评分(NFS)分为T2DM合并进行性肝纤维化组(16例)和T2DM未合并进行性肝纤维化组(64例),收集基本资料和生化指标,采用定量实时PCR方法检测外周血miRNA-128-3p、SIRT1、AMPK的mRNA表达水平,Western Blot方法检测SIRT1、AMPK蛋白表达水平。正态分布的数据两组间比较采用成组t检验,偏态分布的数据两组间比较采用Mann-Whitney U检验,计数资料两组间比较采用χ^(2)检验;Logistic回归分析NAFLD及进行性肝纤维化的影响因素;使用受试者操作特征曲线(ROC曲线)以确定根据miRNA-128-3p水平判断发生NAFLD的最佳阈值。结果合并NAFLD组和T2DM组BMI、空腹血糖、糖化血红蛋白、空腹胰岛素、空腹C肽、ALT、AST、GGT、ALP、纤维连接蛋白、TG、HDL-C、总三碘甲状腺原氨酸(TT3)、胰岛素抵抗指数(HOMA-IR)、NFS比较差异均有统计学意义(P值均<0.05)。合并NAFLD组外周血miRNA-128-3p的mRNA表达水平高于T2DM组(t=-8.765,P<0.001),而SIRT1和AMPK的mRNA及蛋白表达水平均明显降低(P值均<0.001)。T2DM合并进行性肝纤维化组与T2DM未合并进行性肝纤维化组的年龄、ALT、游离三碘甲状腺原氨酸、TT3、超氧化物歧化酶、miRNA-128-3p比较差异均有统计学意义(P值均<0.05)。Logistic回归分析表明,miRNA-128-3p是发生NAFLD和进行性肝纤维化的独立危险因素(OR=8.221,95%CI:2.735~24.714,P<0.001;OR=1.493,95%CI:1.117~1.997,P=0.007);ROC曲线显示其曲线下面积为0.890(95%CI:0.829~0.950),最佳截断值为13.165,敏感度89.3%,特异度72.7%。结论miRNA-128-3p在T2DM合并NAFLD患者外周血中表达增高,SIRT1、AMPK表达降低,miRNA-128-3p水平对识别NAFLD及肝纤维化具有一定诊断价值。 展开更多
关键词 糖尿病 2型 非酒精性脂肪性肝病 微RNAS 抗衰老酶1 AMP活化蛋白激酶类
暂未订购
司美格鲁肽治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床初步研究
8
作者 张磊 王亚茹 +4 位作者 李会平 王帅 张威 周正 张帆 《实用肝脏病杂志》 2025年第5期699-702,共4页
目的观察应用司美格鲁肽联合二甲双胍治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝炎(NASH)患者的临床疗效。方法2022年10月~2023年10月我院诊治的T2DM合并NASH患者80例,被随机分为对照组和观察组,每组40例,分别给予盐酸二甲双胍缓释片或... 目的观察应用司美格鲁肽联合二甲双胍治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝炎(NASH)患者的临床疗效。方法2022年10月~2023年10月我院诊治的T2DM合并NASH患者80例,被随机分为对照组和观察组,每组40例,分别给予盐酸二甲双胍缓释片或在此基础上给予司美格鲁肽皮下注射治疗24周。治疗前后行肝穿刺活检和使用FibroScan-502瞬时弹性成像仪行肝硬度检测(LSM)和检测受控衰减参数(CAP)。结果在治疗24 w末,观察组BMI、空腹血糖、餐后血糖、糖化血红蛋白和HOMA-IR分别为(23.9±0.7)kg/m^(2)、(5.5±0.5)mmol/L、(6.5±1.2)mmol/L、(6.3±0.7)%和(3.6±0.5),均显著低于对照组【分别为(25.6±0.8)kg/m^(2)、(6.0±0.7)mmol/L、(7.9±1.0)mmol/L、(7.5±0.8)%和(4.7±0.7),P<0.05】;观察组血清TG、TC和LDL-C水平分别为(2.7±0.7)mmol/L、(5.1±1.0)mmol/L和(3.3±0.5)mmol/L,均显著低于对照组【分别为(3.4±0.8)mmol/L、(5.8±1.1)mmol/L和(3.7±0.6)mmol/L,P<0.05】,而血清HDL-C水平为(1.3±0.2)mmol/L,显著高于对照组【(1.1±0.2)mmol/L,P<0.05】;观察组肝功能指标改善优于对照组(P<0.05);观察组LSM和CAP分别为(8.6±1.0)kPa和(251.0±18.5)db/m,均显著低于对照组【分别为(10.1±0.9)kPa和(273.0±19.1)db/m,P<0.05】;治疗后,肝组织学检查显示观察组NASH活动度评分(NAS)改善率为72.5%,显著高于对照组的25.0%。结论应用司美格鲁肽联合二甲双胍治疗T2DM合并NASH患者能改善血糖、血脂和肝功能,具有较好的短期疗效。 展开更多
关键词 非酒精性脂肪性肝炎 2型糖尿病 司美格鲁肽 二甲双胍 治疗
暂未订购
剪切波弹性成像联合APRI诊断2型糖尿病合并NAFLD患者肝纤维化程度价值研究 被引量:2
9
作者 曾艾 王聪 +3 位作者 李敏 赵伊婷 张琴 何梅 《实用肝脏病杂志》 2025年第3期382-385,共4页
目的探讨应用剪切波弹性成像检测联合天冬氨酸氨基转移酶/血小板比率指数(APRI)诊断2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者肝纤维化程度的价值。方法2021年1月~2023年12月我院诊治的T2DM合并NAFLD患者73例,使用瞬时弹性成像... 目的探讨应用剪切波弹性成像检测联合天冬氨酸氨基转移酶/血小板比率指数(APRI)诊断2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者肝纤维化程度的价值。方法2021年1月~2023年12月我院诊治的T2DM合并NAFLD患者73例,使用瞬时弹性成像(TE)行肝硬度检测(LSM),使用超声剪切波弹性成像检查获得杨氏模量值。常规临床检测,计算APRI。绘制受试者工作特征(ROC)曲线,分析指标的诊断效能,采用Kappa一致性分析评估剪切波弹性成像联合APRI与TE诊断的一致性。结果以LSM>7.4 kPa诊断为进展期肝纤维化,本组发现进展期肝纤维化患者19例(26.0%);存在进展期肝纤维化患者体质指数、合并糖尿病肾病比率、血清AST、ALT水平、LSM、APRI和杨氏模量值分别为(30.7±2.8)kg/m 2、42.1%、(92.3±10.5)U/L、(120.5±9.6)U/L、(12.7±3.1)kPa、(1.2±0.4)和(10.7±3.1)kPa,均显著高于非进展期肝纤维化患者[分别为(25.2±2.4)kg/m 2、20.4%、(49.8±8.1)U/L、(47.8±7.3)U/L、(6.1±1.6)kPa、(0.8±0.3)和((5.1±1.6))kPa,P<0.05];ROC分析显示杨氏模量值联合APRI诊断T2DM合并NAFLD患者进展期肝纤维化的AUC为0.891,其敏感度为94.7%,特异度为74.1%,显著优于两指标单独预测(P<0.05);剪切波弹性成像联合APRI诊断T2DM合并NAFLD患者进展期肝纤维化与TE检测诊断的Kappa值为0.563(P<0.05),一致性中等。结论剪切波弹性成像联合APRI对T2DM合并NAFLD患者肝纤维化具有一定诊断价值。 展开更多
关键词 非酒精性脂肪性肝病 2型糖尿病 肝纤维化 剪切波弹性成像 天冬氨酸氨基转移酶/血小板比率指数 诊断
暂未订购
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review 被引量:14
10
作者 Henith Raj Harsh Durgia +4 位作者 Rajan Palui Sadishkumar Kamalanathan Sandhiya Selvarajan Sitanshu Sekhar Kar Jayaprakash Sahoo 《World Journal of Diabetes》 2019年第2期114-132,共19页
BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is a common comorbidity with type 2 diabetes.The existing therapeutic options for NAFLD are not adequate.Hypocaloric diet and exercise is the cornerstone of therapy i... BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is a common comorbidity with type 2 diabetes.The existing therapeutic options for NAFLD are not adequate.Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD.Pioglitazone is the only drug recommended in diabetes patients with biopsy proven non-alcoholic steatohepatitis.The frequent coexistence of NAFLD and type 2 diabetes with their combined adverse health consequences and inadequate therapeutic options makes it necessary to search for newer alternatives.AIM To assess the effect of sodium glucose cotransporter-2(SGLT-2)inhibitors on liver enzymes in type 2 diabetes patients with NAFLD.METHODS We searched PubMed/MEDLINE,Cochrane library,Google scholar,and Clinicaltrials.gov for the relevant articles to be included in this systematic review.Human studies done in type 2 diabetes patients with NAFLD treated with SGLT-2 inhibitors for at least 12 wk were included.Data from eight studies(four randomised controlled trials and four observational studies)were extracted and a narrative synthesis was done.A total of 214 patients were treated with SGLT-2 inhibitors in these studies(94 in randomised controlled trials and 120 in observational studies).RESULTS The primary outcome measure was change in serum alanine aminotransferase level.Out of eight studies,seven studies showed a significant decrease in serum alanine aminotransferase level.Most of the studies revealed reduction in serum level of other liver enzymes like aspartate aminotransferase and gamma glutamyl transferase.Five studies that reported a change in hepatic fat exhibited a significant reduction in hepatic fat content in those treated with SGLT-2 inhibitors.Likewise,among the three studies that evaluated a change in indices of hepatic fibrosis,two studies revealed a significant improvement in liver fibrosis.Moreover,there was an improvement in obesity,insulin resistance,glycaemia,and lipid parameters in those subjects taking SGLT-2 inhibitors.The studies disclosed that about 17%(30/176)of the subjects taking SGLT-2 inhibitors developed adverse events and more than 40%(10/23)of them had genitourinary tract infections.CONCLUSION Based on low to moderate quality of evidence,SGLT-2 inhibitors improve the serum level of liver enzymes,decrease liver fat,and fibrosis with additional beneficial effects on various metabolic parameters in type 2 diabetes patients with NAFLD. 展开更多
关键词 ALANINE AMINOTRANSFERASE HEPATIC fat HEPATIC fibrosis Non-alcoholic fatty liver disease Sodium-glucose cotransporter-2 inhibitor type 2 diabetes MELLITUS
暂未订购
焦甜醇甜香型与清甜香型烟叶化学成分及感官质量差异分析
11
作者 蔡联合 苏赞 +2 位作者 梁伟 陈义昌 邹克兴 《黑龙江农业科学》 2025年第8期101-106,共6页
为探明焦甜醇甜香型烟叶和清甜香型烟叶的质量和烟气风格,更好地指导卷烟配方用烟,分析了两种香型烟叶在化学成分和感官质量间的差异。结果表明,清甜香型烟叶的总糖、还原糖含量显著高于焦甜醇甜香型烟叶,两种香型C3FA烟叶的总糖含量分... 为探明焦甜醇甜香型烟叶和清甜香型烟叶的质量和烟气风格,更好地指导卷烟配方用烟,分析了两种香型烟叶在化学成分和感官质量间的差异。结果表明,清甜香型烟叶的总糖、还原糖含量显著高于焦甜醇甜香型烟叶,两种香型C3FA烟叶的总糖含量分别为31.0%和27.4%,还原糖含量分别为26.3%和22.0%,C3F烟叶的总糖含量分别为27.0%和20.2%,还原糖含量分别为23.3%和16.1%;化学成分协调性上清甜香型烟叶的糖碱比表现较好,清甜香型C3FA和C3F烟叶的糖碱比分别为10.31和8.38,而钾氯比表现欠佳;两种香型烟叶在多酚类物质含量上的差异较大,清甜香型烟叶除莨菪亭外,其余酚类物质含量均高于焦甜醇甜香型烟叶,两种香型C3FA烟叶总酚类物质含量分别36.82和24.55 mg·g^(-1),C3F烟叶的总酚类物质含量分别为38.94和25.16 mg·g^(-1);两类型烟叶中的非挥发性有机酸均以苹果酸含量最高,且焦甜醇甜香型烟叶的苹果酸含量明显高于清甜香型烟叶,焦甜醇甜香型C3FA烟叶的苹果酸含量为47.2 mg·g^(-1),C3F烟叶的苹果酸含量为64.8 mg·g^(-1)。在感官质量上,两种类型烟叶的香韵特征差异较大,其中清甜香型烟叶的香韵表现更为丰富,主要以干草香和清甜香为主,而焦甜醇甜香型烟叶主要以干草香和焦甜香为主。 展开更多
关键词 焦甜醇甜香型 清甜香型 烟叶 化学成分 感官质量
在线阅读 下载PDF
Effects of Aerobic Exercise on the Intramuscular Lipid and Glycogen Content of Fiber Types in Soleus Muscles of Non-Alcoholic Steatohepatitis Model Rats
12
作者 Miyako Mochizuki Emi Hayashi +3 位作者 Atsushi Yoshimura Yuko Toyoda Lin Mei Noboru Hasegawa 《Open Journal of Endocrine and Metabolic Diseases》 2015年第10期131-137,共7页
We studied the effects of exercise on muscle mitochondria, and lipid and glycogen content in non-alcoholic steatohepatitis (NASH) model rats. Male Sprague-Dawley rats were randomly separated into 3 groups: the control... We studied the effects of exercise on muscle mitochondria, and lipid and glycogen content in non-alcoholic steatohepatitis (NASH) model rats. Male Sprague-Dawley rats were randomly separated into 3 groups: the control group was fed standard chow;the NASH group was fed a methionine-choline-deficient high-fat diet (MCD);the NASH-exercise group was fed the MCD and exercised three times a week. Exercise training consisted of continuous running for thirty minutes at a 13 m/min, 6° slope on a motor-driven rodent treadmill for 6 weeks. Mitochondria content in NASH group decreased in the both fiber types compared with those of the control group. As compared between the NASH and NASH-exercise groups, however, exercise not only promoted significant improvements in liver fibrosis and cirrhosis and triglyceride (TG) content but also increased mitochondria content in type I muscle fiber in particular. These data suggest that exercise improved hepatic steatosis in NASH model rats and can prevent the progression of NASH. 展开更多
关键词 Metabolic Disease Non-alcoholic STEATOHEPATITIS INTRAMUSCULAR Lipid TRIGLYCERIDE GLYCOGEN HISTOPATHOLOGICAL Fiber types Aerobic Exercise
暂未订购
慢性心力衰竭合并NAFLD的临床特征及影响因素
13
作者 苏蓉 林玲 +4 位作者 赵渊 杨爱玲 张明国 张浒 马国玉 《昆明医科大学学报》 2025年第8期65-71,共7页
目的了解慢性心力衰竭(chronic heart failure,CHF)合并非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的患病率、临床特征及其危险因素,为NAFLD的早期识别提供参考。方法收集1120例14~89岁的CHF患者资料,包括年龄、性... 目的了解慢性心力衰竭(chronic heart failure,CHF)合并非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的患病率、临床特征及其危险因素,为NAFLD的早期识别提供参考。方法收集1120例14~89岁的CHF患者资料,包括年龄、性别、是否吸烟、身高、体重和BMI等资料,临床诊疗资料(血压、NYHA心功能分级、病因、血生化指标等)及用药情况。采用SPSS27.0分析CHF合并NAFLD的临床特点,采用多因素Logistic回归分析方法分析CHF合并NAFLD的独立危险因素。结果1120例患者中,男性634例(56.6%)、女性486例(43.4%)。CHF患者合并NAFLD的患病率为25.0%。单因素分析结果显示,NAFLD患者的体重、BMI、收缩压、舒张压、FPG(空腹血糖)、UA(血尿酸)、左房扩大比例、ALT、CHO、TG和β-受体阻滞剂使用率均高于非NAFLD患者,NAFLD患者的年龄、BNP、HDL和ACEI/ARB/ARNI使用率均低于非NAFLD患者(P<0.05)。Logistic回归分析显示,年龄(OR=0.988)、空腹血糖(OR=1.099)、超重(OR=3.497)、肥胖(OR=9.193)是CHF患者合并NAFLD的独立危险因素。结论NAFLD可能是CHF患者尤其是年龄较轻、空腹血糖较高、超重和肥胖CHF患者的常见合并症,在临床上,应重视年龄较轻、空腹血糖较高、超重及肥胖的CHF患者的NAFLD筛查、评估及管理。 展开更多
关键词 慢性心力衰竭 非酒精性脂肪性肝病 肥胖 2型糖尿病
暂未订购
三酰甘油葡萄糖指数与早发2型糖尿病合并非酒精性脂肪性肝病的关系
14
作者 李居一 王郡华 +5 位作者 王晓倩 张媛媛 武妮妮 胡海英 李美美 刘怀珍 《中国临床保健杂志》 2025年第4期500-507,共8页
目的探讨三酰甘油葡萄糖(TyG)指数与早发2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)之间的关系。方法回顾性分析2023年1月至2024年6月在安徽中医药大学第一附属医院住院的506例T2DM患者的临床资料。将早发T2DM并有NAFLD的患者归为早... 目的探讨三酰甘油葡萄糖(TyG)指数与早发2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)之间的关系。方法回顾性分析2023年1月至2024年6月在安徽中医药大学第一附属医院住院的506例T2DM患者的临床资料。将早发T2DM并有NAFLD的患者归为早发T2DM合并NAFLD组(51例),其余T2DM患者归为对照组(455例)。506例中,早发T2DM患者共109例,根据是否合并NAFLD分为合并NAFLD组(51例)和未合并NAFLD组(58例),观察2组临床资料。采用多因素logistic回归探究早发T2DM合并NAFLD的影响因素;限制性立方样条曲线(RCS)计算TyG指数与早发T2DM合并NAFLD的剂量反应关系,受试者工作特征(ROC)曲线评价TyG指数的诊断效能。结果早发T2DM合并NAFLD组和对照组患者的性别、年龄、体重指数(BMI)、TyG、TyG-BMI、舒张压(DBP)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FIns)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、白蛋白(Alb)、γ-谷氨酰转移酶(GGT)、尿素氮(BUN)、尿酸(UA)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)差异均有统计学意义(均P<0.05)。早发T2DM合并NAFLD组和未合并NAFLD组患者的病程、BMI、TyG、TyG-BMI、收缩压(SBP)、DBP、FPG、FIns、空腹C肽(FCP)、ALT、AST、GGT、BUN、UA、TG、HDL-C、糖尿病肾脏病(DKD)的发生率比较,差异均有统计学意义(均P<0.05)。logistic回归分析显示,TyG指数是早发T2DM合并NAFLD发生的独立危险因素。在男性、肥胖、ALT≥18 U/L、UA≥326μmol/L、尿白蛋白肌酐比≥30 mg/g的亚组中,TyG指数与早发T2DM合并NAFLD患病风险的关联能观察到类似结果(均P<0.05)。RCS显示,TyG指数与早发T2DM合并NAFLD的患病风险存在线性剂量反应关系(P-overall<0.05、P-nonlinear=0.397)。ROC曲线下面积为0.728(95%CI:0.634~0.821),最佳截断值为7.520,灵敏度74.5%,特异度62.1%。结论早发T2DM合并NAFLD的发病风险随TyG指数的升高而增加,TyG指数可作为早发T2DM合并NAFLD的有效预测指标。 展开更多
关键词 糖尿病 2型 非酒精性脂肪性肝病 三酰甘油葡萄糖 危险因素
暂未订购
苍附导痰丸加味联合西药治疗痰浊内阻型非酒精性脂肪性肝炎疗效观察
15
作者 余松 何杰 赵秋凤 《北京中医药》 2025年第6期721-724,共4页
目的观察苍附导痰丸加味联合西药治疗痰浊内阻型非酒精性脂肪性肝炎(NASH)的临床疗效。方法选取2022年1月—2023年12月在本院确诊为痰浊内阻型NASH的患者96例,按随机数字表法分为对照组和观察组,每组48例。对照组予多烯磷脂酰胆碱胶囊口... 目的观察苍附导痰丸加味联合西药治疗痰浊内阻型非酒精性脂肪性肝炎(NASH)的临床疗效。方法选取2022年1月—2023年12月在本院确诊为痰浊内阻型NASH的患者96例,按随机数字表法分为对照组和观察组,每组48例。对照组予多烯磷脂酰胆碱胶囊口服,2粒/次,3次/d。观察组在对照组治疗的基础上加用中药颗粒剂苍附导痰丸加味冲服,1剂/d。2组疗程均为12周。对比2组治疗前后生化指标(ALT、AST、GGT、TC、TG)、肝脏脂肪含量[受控衰减参数(CAP)值]、中医证候积分,观察肝脏脂肪含量疗效、中医证候疗效及安全性。结果治疗12周,2组生化指标均较治疗前均降低(P<0.05),且观察组GGT、TC、TG低于对照组(P<0.05)。治疗后,对照组、观察组CAP均较治疗前降低(P<0.05),且观察组低于对照组。观察组肝脏脂肪含量治疗总有效率高于对照组(P<0.05)。治疗后,对照组、观察组中医证候积分均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。观察组中医证候治疗总有效率为95.8%,高于对照组的81.3%(χ^(2)=5.031,P<0.05)。2组安全性指标检测无异常,且治疗过程中均未出现发热、皮疹、恶心呕吐等不适症状。结论苍附导痰丸加味联合西药可改善痰浊内阻型NASH患者肝功能、降低肝脏脂肪含量、改善中医证候,且安全性较高。 展开更多
关键词 苍附导痰丸 非酒精性脂肪性肝炎 痰浊内阻型
原文传递
玉泉胶囊对2型糖尿病合并非酒精性脂肪性肝病患者糖脂代谢功能的影响
16
作者 范国洽 曹柳 刘珊 《中国药业》 CAS 2025年第1期86-89,共4页
目的探讨玉泉胶囊对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者糖脂代谢功能的影响。方法选取医院2023年2月至12月收治的T2DM合并NAFLD患者100例,按随机数字表法分为观察组和对照组,各50例,两组各剔除1例,最终各纳入49例。两组... 目的探讨玉泉胶囊对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者糖脂代谢功能的影响。方法选取医院2023年2月至12月收治的T2DM合并NAFLD患者100例,按随机数字表法分为观察组和对照组,各50例,两组各剔除1例,最终各纳入49例。两组患者均予二甲双胍,并结合饮食控制,观察组患者加用玉泉胶囊,两组患者均连续治疗6个月。结果观察组总有效率为87.76%,显著高于对照组的67.35%(P<0.05);治疗后,观察组患者的空腹血糖、糖化血红蛋白、餐后2 h血糖、低密度脂蛋白胆固醇、胰岛素抵抗指数均显著低于对照组,高密度脂蛋白胆固醇显著高于对照组(P<0.05);观察组患者的血清γ-谷氨酰基转移酶、天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、体质量指数、非酒精性脂肪性肝纤维化评分(NAFLDFS)、超声肝脏回声衰减系数和肝肾回声比值均显著低于对照组(P<0.05)。观察组和对照组不良反应发生率相当(12.24%比8.16%,P>0.05)。结论玉泉胶囊治疗T2DM合并NAFLD的临床疗效较好,可有效改善患者的糖脂代谢功能,减轻胰岛素抵抗,延缓NAFLD进展,且安全性良好。 展开更多
关键词 玉泉胶囊 2型糖尿病 非酒精性脂肪性肝病 糖脂代谢 肝功能
暂未订购
2型糖尿病患者非酒精性脂肪肝与内脏脂肪面积及甲状腺结节的相关性研究 被引量:5
17
作者 曾佳玲 蒙艳 +2 位作者 邓婷婷 李锦华 赵萍 《中国全科医学》 北大核心 2025年第9期1072-1083,共12页
背景非酒精性脂肪肝(NAFLD)在2型糖尿病(T2DM)患者中患病率明显升高,目前关于T2DM中NAFLD与内脏脂肪面积(VFA)及甲状腺结节的相关研究鲜有报道。目的 探讨T2DM患者发生NAFLD的相关因素及NAFLD与VFA、甲状腺结节及甲状腺功能的相关性。方... 背景非酒精性脂肪肝(NAFLD)在2型糖尿病(T2DM)患者中患病率明显升高,目前关于T2DM中NAFLD与内脏脂肪面积(VFA)及甲状腺结节的相关研究鲜有报道。目的 探讨T2DM患者发生NAFLD的相关因素及NAFLD与VFA、甲状腺结节及甲状腺功能的相关性。方法 回顾性选择2018年1月—2023年4月在广西医科大学第四附属医院(柳州市工人医院)内分泌科住院的T2DM患者为研究对象,依据腹部彩超结果将研究对象分为NAFLD组及非NAFLD组,比较两组的一般资料,VFA、腹部皮下脂肪面积(SFA)、胰岛素功能、甲状腺功能、甲状腺结节患病率、血糖、血脂、肝肾功能水平等指标的差异。依据VFA将研究对象分为内脏性肥胖组(VFA≥100 cm^(2))和非内脏性肥胖组(VFA<100 cm^(2)),比较两组年龄、性别、NAFLD及甲状腺结节患病率的差异。使用Spearman秩相关分析探讨NAFLD、VFA的相关因素及两者与甲状腺结节的相关性分析,同时探讨甲状腺结节面积大小的相关因素。采用二元Logistic回归分析明确T2DM患者NAFLD及甲状腺结节发生的危险因素。采用受试者工作特征(ROC)曲线评估BMI、腰臀围、腰臀比、VFA、胰岛素抵抗指数(HOMA-IR)对T2DM患者发生NAFLD的预测价值及最佳截断值。结果 本研究共纳入578例T2DM患者,NAFLD组293例,NAFLD患病率50.69%,非NAFLD组285例。NAFLD组年龄小于非NAFLD组[(57.0±12.8)岁与(59.3±11.6)岁,P<0.05],NAFLD组体质量、BMI、腰围、臀围、VFA、SFA、糖化血红蛋白(HbA_(1c))、空腹胰岛素(FINS)、空腹C肽(FCP)、HOMA-IR、胰岛素分泌指数(HOMA-β)、游离三碘甲状腺原氨酸(FT_(3))、血尿酸(SUA)、总胆固醇(TC)、三酰甘油(TG)、C反应蛋白(CRP)均高于非NAFLD组,但其血肌酐(SCr)水平低于非NAFLD组(P<0.05)。内脏性肥胖组251例,非内脏性肥胖组327例,内脏性肥胖组年龄小于非内脏性肥胖组[(55.3±13.4)岁与(60.3±10.8)岁,P<0.05]。内脏性肥胖组患者NAFLD发生率高于非内脏性肥胖组(P<0.05)。内脏性肥胖组与非内脏性肥胖组甲状腺结节患病率(64.94%与59.82%)比较,差异无统计学意义(P>0.05)。Spearman秩相关分析显示:T2DM患者发生NAFLD与体质量、BMI、腰围、臀围、腰臀比、VFA、SFA、HbA_(1c)、FINS、FCP、HOMA-IR、HOMA-β、总三碘甲状腺原氨酸(TT_(3))、FT_(3)、CRP呈正相关(P<0.05),与年龄呈负相关(P<0.05)。T2DM患者VFA与性别、年龄、身高、体质量、BMI、腰围、臀围、腰臀比、SFA、舒张压、FINS、FCP、HOMA-IR、HOMA-β、TT_(3)、FT_(3)、CRP、NAFLD相关(P<0.05);甲状腺结节面积大小与身高、促甲状腺激素(TSH)、腰臀比呈负相关(P<0.05),与性别、年龄、TT_(3)、总甲状腺素(TT_(4))、甲状腺球蛋白呈正相关(P<0.05)。单因素非条件Logistic回归分析显示,年龄、体质量、BMI、腰围、臀围、VFA、SFA、HbA_(1c)、FCP、HOMA-IR、FT_(3)、SCr、SUA、TC、TG是T2DM患者发生NAFLD的影响因素;二元Logistic回归分析显示,体质量(OR=0.962)、VFA(OR=1.025)、SFA(OR=1.006)、FT_(3)(OR=1.429)、HOMA-IR(OR=1.140)是T2DM发生NAFLD的影响因素;性别(OR=0.342)、年龄(OR=1.073)、游离甲状腺素(FT_(4))(OR=1.140)是甲状腺结节的影响因素(P<0.05)。ROC曲线结果显示,各指标预测T2DM患者发生NAFLD的ROC曲线下面积依次为:BMI0.704、腰围0.704、臀围0.705、腰臀比0.629、VFA 0.757、HOMA-IR 0.569,最佳截断值依次为:BMI 25.37 kg/m^(2)(灵敏度67.7%,特异度36.0%)、腰围84.5 cm(灵敏度67.3%,特异度36.4%)、臀围96.5 cm(灵敏度69.4%,特异度38.9%)、腰臀比0.895(灵敏度38.8%,特异度19.1%)、VFA88.4 cm^(2)(灵敏度78.9%,特异度35.3%)(其中女性88.40 cm^(2),男性99.45 cm^(2))、HOMA-IR 3.08(灵敏度64.3%,特异度49.8%)。结论 T2DM患者NAFLD与甲状腺结节患病率明显升高,但两者之间无明显相关性。肥胖的T2DM患者,尤其内脏性肥胖患者更易罹患NAFLD、甲状腺结节及高脂血症、高尿酸血症等代谢性疾病。HOMA-IR是T2DM患者发生NAFLD的影响因素之一,但不是T2DM患甲状腺结节的影响因素。BMI、腰围、臀围、VFA均可用于预测T2DM患者发生NAFLD,但VFA的预测价值最高,HOMA-IR的价值最低;VFA预测T2DM患者NAFLD最佳截断值为88.4 cm^(2),女性与总体一致,男性为99.45 cm^(2)。 展开更多
关键词 糖尿病 2型 非酒精性脂肪性肝病 内脏脂肪 甲状腺疾病 甲状腺结节 胰岛素抵抗
暂未订购
吡格列酮二甲双胍治疗T2DM合并NAFLD患者的疗效与安全性
18
作者 王海敏 田德增 李晓燕 《中国药物应用与监测》 2025年第7期1187-1191,共5页
目的探究吡格列酮二甲双胍复方制剂在2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者中的疗效和安全性。方法选取濮阳市安阳地区医院2023年9月至2024年9月收治的140例T2DM合并NAFLD患者,通过计算机生成的随机序列分为两组,每组70例... 目的探究吡格列酮二甲双胍复方制剂在2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者中的疗效和安全性。方法选取濮阳市安阳地区医院2023年9月至2024年9月收治的140例T2DM合并NAFLD患者,通过计算机生成的随机序列分为两组,每组70例。观察组服用吡格列酮二甲双胍片(盐酸吡格列酮15 mg和盐酸二甲双胍500 mg),初始剂量为每次1片,每日1次,早餐或晚餐前口服,治疗1周后调整为每次1片,每日2次,早餐和晚餐前口服。对照组服用盐酸二甲双胍片,每次0.5 g,每日1次,早餐或晚餐前口服,治疗1周后调整为每次0.5 g,每日2次,早餐和晚餐前口服。两组均持续治疗6个月,比较两组患者治疗前后的肝功能指标、体质量、腰围、炎症指标、糖代谢水平和不良反应发生情况。结果治疗后,两组丙氨酸氨基转移酶、天冬氨酸氨基转移酶和γ-谷氨酰转肽酶水平均下降,且观察组[(26.37±4.55)IU/L、(21.58±5.22)IU/L、(30.99±3.04)IU/L]低于对照组[(32.63±5.02)IU/L、(23.66±5.90)IU/L、(40.55±3.43)IU/L](t=7.730、2.209、17.451,均P<0.05)。治疗后,两组体质量、腰围、外异蛋白A、白细胞介素1β和肿瘤坏死因子α均较治疗前降低,且观察组[(67.58±11.58)kg、(86.58±5.22)cm、(92.80±12.50)ng/L、(6.09±0.81)pg/mL、(13.13±1.33)pg/mL]低于对照组[(72.05±12.97)kg、(91.66±5.90)cm、(135.51±24.30)ng/L、(7.97±0.58)pg/mL、(19.58±1.87)pg/mL](t=2.150、5.395、12.747、15.787、23.517,均P<0.05)。治疗后,两组糖化血红蛋白、空腹血糖和胰岛素抵抗指数均较治疗前改善(P<0.05),观察组胰岛素抵抗指数较对照组降低[(2.60±0.49)vs(2.89±0.52)](t=3.396,P<0.05),但糖化血红蛋白、空腹血糖水平[(6.35±0.58)%、(6.78±1.19)mmol/L]和对照组[(6.50±0.86)%、(6.89±1.84)mmol/L]比较差异无统计学意义(t=1.210、0.420,均P>0.05)。观察组的不良反应发生率(7.14%,5/70)低于对照组(20.00%,14/70),差异有统计学意义(χ^(2)=4.933,P<0.05)。结论吡格列酮二甲双胍治疗6个月能够有效改善T2DM合并NAFLD患者的肝功能、炎症指标和糖代谢水平,降低不良反应的发生率。 展开更多
关键词 吡格列酮 二甲双胍 外异蛋白A 白细胞介素1Β 2型糖尿病 非酒精性脂肪性肝病
暂未订购
补肾健脾方治疗2型糖尿病合并非酒精性脂肪肝病的疗效观察
19
作者 李燕 刘峰 +2 位作者 张杰文 林靖 季兵 《广州中医药大学学报》 2025年第11期2705-2713,共9页
【目的】观察补肾健脾方治疗脾肾两虚型2型糖尿病(T2DM)合并非酒精性脂肪肝病(NAFLD)的临床疗效。【方法】选取2023年6月至2024年9月期间广东祈福医院收治的脾肾两虚型T2DM合并NAFLD患者72例,采用随机数字表法将患者随机分为治疗组和对... 【目的】观察补肾健脾方治疗脾肾两虚型2型糖尿病(T2DM)合并非酒精性脂肪肝病(NAFLD)的临床疗效。【方法】选取2023年6月至2024年9月期间广东祈福医院收治的脾肾两虚型T2DM合并NAFLD患者72例,采用随机数字表法将患者随机分为治疗组和对照组,每组各36例。对照组给予生活方式干预及二甲双胍口服治疗,治疗组在对照组的基础上加用补肾健脾方治疗,连续干预12周。观察2组患者治疗前后中医证候积分、肝功能指标、脂肪肝B超分度、糖脂代谢指标的变化情况,并评价2组患者的临床疗效和用药安全性。【结果】(1)脱落情况方面,研究过程中,治疗组有2例患者脱落,对照组无病例脱落,最终治疗组有34例、对照组有36例患者完成疗效评估。(2)临床疗效方面,治疗12周后,治疗组的总有效率88.24%(30/34),对照组为66.67%(24/36),组间比较(χ^(2)检验),治疗组的疗效明显优于对照组(P<0.05)。(3)肝功能指标方面,治疗后,2组患者的血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)水平均较治疗前降低(P<0.05),且治疗组的降低幅度均明显优于对照组(P<0.05)。(4)脂肪肝B超分度方面,治疗后,2组患者的脂肪肝B超分度均较治疗前改善(P<0.05),且治疗组的改善幅度明显优于对照组(P<0.05)。(5)糖脂代谢指标方面,治疗后,2组患者的空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前降低(P<0.05),且治疗组的降低幅度均明显优于对照组(P<0.05);而2组患者的高密度脂蛋白胆固醇(HDL-C)水平均较治疗前升高(P<0.05),且治疗组的升高幅度均明显优于对照组(P<0.05)。(6)中医证候积分方面,治疗后,2组患者的中医证候积分均较治疗前降低(P<0.05),且治疗组的降低幅度明显优于对照组(P<0.05)。(7)安全性方面,治疗过程中,2组患者的血、尿、大便常规和肾功能指标及心电图均无异常变化;治疗组的不良反应发生率为2.94%(1/34),对照组为5.56%(2/36),组间比较,差异无统计学意义(P>0.05)。【结论】补肾健脾方联合二甲双胍治疗脾肾两虚型T2DM合并NAFLD患者的临床疗效明显优于单纯二甲双胍治疗,补肾健脾方能减轻患者临床症状,提高中医证候疗效,降低肝功能酶学指标,改善脂肪肝B超分度,并能有效改善胰岛素抵抗,调节血糖、血脂水平。 展开更多
关键词 补肾健脾方 二甲双胍 2型糖尿病 非酒精性脂肪性肝病 脾肾两虚型 糖脂代谢 肝功能 胰岛素抵抗
原文传递
GLP-1RA对2型糖尿病合并非酒精性脂肪性肝病大鼠肝组织病变及氧化应激损伤的影响
20
作者 余玲 段程慧 +2 位作者 杨洋 董瑞鸿 桑艳红 《中西医结合肝病杂志》 2025年第3期335-339,共5页
目的:研究胰高血糖素样肽-1受体激动剂(GLP-1RA)对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)大鼠肝组织病变及氧化应激损伤的影响。方法:6只SD大鼠正常饲养作对照组,取SD大鼠给予高脂饮食联合链脲佐菌素构建T2DM合并NAFLD模型,造... 目的:研究胰高血糖素样肽-1受体激动剂(GLP-1RA)对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)大鼠肝组织病变及氧化应激损伤的影响。方法:6只SD大鼠正常饲养作对照组,取SD大鼠给予高脂饮食联合链脲佐菌素构建T2DM合并NAFLD模型,造模成功后随机分为模型组、GLP-1RA组,每组6只,对照组和模型组腹腔注射生理盐水,GLP-1RA组腹腔注射GLP-1RA治疗,4周后观察大鼠一般情况并检测其体重、肝湿重、肝指数、生化指标[血糖(GLU)、糖化血清蛋白(GSP)、总胆固醇(TC)、甘油三酯(TG)、丙氨酸氨基转移酶(ALT)]水平;以HE、油红O染色分别检测大鼠肝组织病理形态及脂肪变性;试剂盒检测大鼠肝组织氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)]水平。结果:与对照组相比,模型组大鼠肝组织发生明显病理损伤与脂肪变性,体重、肝湿重、肝指数、GLU、GSP、TC、TG与ALT水平、NFALD活动度积分、肝组织MDA水平显著升高(P<0.05),肝组织SOD水平显著降低(P<0.05);与模型组相比,GLP-1RA组大鼠肝组织病理损伤与脂肪变性减轻,体重、肝湿重、肝指数、GLU、GSP、TC、TG与ALT水平、NFALD活动度积分、肝组织MDA水平降低(P<0.05),肝组织SOD水平升高(P<0.05)。结论:GLP-1RA可改善T2DM合并NAFLD大鼠糖脂代谢,拮抗氧化应激,减少肝脏细胞内脂质沉积,减轻大鼠肝组织病变与氧化应激损伤,保护肝功能,延缓NAFLD进展。 展开更多
关键词 高血糖素样肽-1受体激动剂 2型糖尿病 非酒精性脂肪性肝病 肝组织病变 氧化应激损伤
暂未订购
上一页 1 2 41 下一页 到第
使用帮助 返回顶部